EUVIMEDEUVIMED entdecken
Crossref

A clinical study of RC48-ADC combined with PD-1 inhibitor in bladder preservation therapy for muscle-invasive bladder cancer (MIBC)—based on real-world data analysis

Shaolong Zhang, Chuanjian Chen, Chunhao Mo, Ning Fan, Zhongyun Ning, Zhiping Wang, Hui Ding

International Urology and Nephrology · 14.05.2025 · 57 (12) · 3993-4001

DOI: 10.1007/s11255-025-04567-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Urology and Nephrology, online erschienen am 14.05.2025. Verfasst von Shaolong Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Gansu Province Clinical Research Center for urinary system disease, The Second Hospital & Clinical Medical School, Lanzhou Uni…. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Urinary Bladder, Immune Checkpoint Inhibitors, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Department of Science and Technology of Gansu Province, Basic research of science and technology innovation application - surface project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsUrinary BladderImmune Checkpoint InhibitorsAntineoplastic Combined Chemotherapy ProtocolsAntibodies, MonoclonalOrgan Sparing TreatmentsRetrospective StudiesProgression-Free SurvivalImmunoconjugatesInjections, IntravenousOligopeptidesAntibodies, Monoclonal, HumanizedProgrammed Cell Death 1 ReceptorNeoplasm StagingFollow-Up StudiesHumansMaleFemaleMiddle AgedAgedAged, 80 and over

Stichwörter der Autor:innen

Bladder preservation therapyImmune combination therapyMuscle-invasive bladder cancerPD-1 inhibitorRC48-ADC

Substanzen

Immune Checkpoint Inhibitorsdisitamab vedotinImmunoconjugatesAntibodies, MonoclonalOligopeptidestislelizumabtoripalimabAntibodies, Monoclonal, HumanizedPDCD1 protein, humanProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Department of Urology, Gansu Province Clinical Research Center for urinary system disease, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
  • Department of Urology, Gansu Province Clinical Research Center for urinary system disease, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China. dingh08@126.com.

Förderung

  • Department of Science and Technology of Gansu Province
  • Basic research of science and technology innovation application - surface project

Zitieren

APA

Zhang, S., Chen, C., Mo, C., Fan, N., Ning, Z., Wang, Z., & Ding, H. (2025). A clinical study of RC48-ADC combined with PD-1 inhibitor in bladder preservation therapy for muscle-invasive bladder cancer (MIBC)—based on real-world data analysis. International Urology and Nephrology, 57(12), 3993-4001. https://doi.org/10.1007/s11255-025-04567-2

Vancouver

Zhang S, Chen C, Mo C, Fan N, Ning Z, Wang Z, et al. A clinical study of RC48-ADC combined with PD-1 inhibitor in bladder preservation therapy for muscle-invasive bladder cancer (MIBC)—based on real-world data analysis. International Urology and Nephrology. 2025;57(12):3993-4001. doi:10.1007/s11255-025-04567-2

BibTeX
@article{Zhang2025,
  author = {Zhang, Shaolong and Chen, Chuanjian and Mo, Chunhao and Fan, Ning and Ning, Zhongyun and Wang, Zhiping and Ding, Hui},
  title = {A clinical study of RC48-ADC combined with PD-1 inhibitor in bladder preservation therapy for muscle-invasive bladder cancer (MIBC)—based on real-world data analysis},
  journal = {International Urology and Nephrology},
  year = {2025},
  volume = {57},
  number = {12},
  pages = {3993--4001},
  doi = {10.1007/s11255-025-04567-2}
}
Kostenlos starten →